Abstract library

40 results for "Pande".
#903 Health-Related Quality-of-Life (HRQoL) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) Treated with Everolimus (EVE): Results from an Open-label, Phase IIIb, Multicenter, Expanded Access Program (EAP)
Introduction: NET is associated with a considerable HRQoL burden.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Marianne Pavel
Authors: Pavel M, Unger N, Borbath I, Ricci S, ...
Keywords: everolimus, QoL, NET
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#545 A Case of ACTH-Secreting Bronchial Carcinoid
Introduction: Ectopic ACTH syndrome (EAS) occurs in about 5-10% of ACTH-dependent hypercortisolism and, in up to 15% of cases, is related to occult neoplasms.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#601 Chromogranin A is a Sensitive Marker of Progression or Regression
Introduction: One of the most common is gastroenteropancreatic (GEP) NET of the pancreas, which constitute about 30% of all GEP NET. CgA is an excellent marker for NET and tumor volume and plasma CgA is suggested as the most reliable marker in follow-up of GEP but only few studies have been published.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Kenneth Jensen
#696 Downgrading Due to Ki-67 Index Assessment with Image Analysis
Introduction: The latest WHO classification for neuroendocrine tumors (NET) defines their grade according to Ki-67 and mitotic index. These parameters have both shown to be prognostic.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Marie-Louise Van Velthuysen
#797 Ganglioneuroma of Retroperitoean
Introduction: Ganglioneuromas presented as a retroperitoneal tumor around vital organs is a rare entity. A case with unusual presentation is reported. Forty-four-year-old woman presented without any complaint, found during incidental abdominopelvic ultrasound.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: medical oncology Mehrdad Payandeh
Authors: payandeh M, aeinfar M, ...
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#1078 Somatostatin Responsive ACTH and Precursor Excess in a Midgut Mesentery NET
Introduction: ACTH production from a midgut mesentery NET is extremely rare (1). A 62y old woman presented with hypokalaemia (2mmol/L) and hyperpigmentation, 11y after surgery of a pT3N1Mx non-functional G1 NET with SRS positive, non-resectable but stable, residual mass encasing mesenteric vessels. Serum cortisol (3261 nmol/L), ACTH (796 ng/L), CgA (530 pmol/L) and urine total cortisol metabolites (33920 µg/24h) including 14 sub-products indicated change of biological behaviour into a functioning NET. Pituitary or pulmonary sources were excluded
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr., Ass Prof. Martin O. Weickert
#1141 New Hybrid SPECT-CT Modality for Imaging Purposes in Patients with Medullary Thyroid Cancer (MTC)
Introduction: Loco-regional lymph node and distant metastases are found very often in patients with MTC of less than 1 cm. There is not good MTC response to systemic chemotherapy or to external been radiotherapy. Radical thyroidectomy is the main method of therapy. Early diagnosis and correct N/M-staging are extremely important for the management of MTC. New hybrid SPECT-CT γ-cameras allow the fusion of anatomical and functional modalities. SPECT-CT is used in order to optimize somatostatin-receptor scintigraphic protocols.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Sonya Sergieva
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.